Neuroendocrine Tumors

Oncology·MeSH: Neuroendocrine Tumors

17 drugs in development·11 companies·22 clinical trials

Drug Pipeline by Phase

Approved(3)

Phase 3(4)

Drug	Company
177lu-pnt2003	POINT Biopharma Global Inc. (PNT)
lutetium[177lu] oxodotreotide	SPRING PHARMACEUTICAL GROUP, INC. (CYIG)
octreotide lar	SPRING PHARMACEUTICAL GROUP, INC. (CYIG)
pnt2003	POINT Biopharma Global Inc. (PNT)

Phase 2(1)

Drug	Company
fyarro	Whitehawk Therapeutics, Inc. (WHWK)

Phase 1(1)

Drug	Company
pelcitoclax	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)

Preclinical(1)

Drug	Company
Pb212-VMT-⍺-NET	Lantheus Holdings, Inc. (LNTH)

BLA Filed(1)

Drug	Company
PNT2003	Lantheus Holdings, Inc. (LNTH)

N/A(1)

Drug	Company
Pb212-VMT-α-NET	Lantheus Holdings, Inc. (LNTH)

Phase 1/Phase 2(3)

Drug	Company
[203pb]vmt-α-net	Perspective Therapeutics, Inc. (CATX)
[212pb]vmt-α-net	Perspective Therapeutics, Inc. (CATX)
VMT-α-NET	Perspective Therapeutics, Inc. (CATX)

Phase 2/Phase 3(2)

Drug	Company
surufatinib	HUTCHMED (China) Limited (HCM)
surufatinib	HUTCHMED (China) Ltd (HMDCF)

BioSniper tracks 17 drugs in development for Neuroendocrine Tumors across 11 companies.

There are 22 clinical trials targeting Neuroendocrine Tumors tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.